
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genflow Biosciences Plc | LSE:GENF | London | Ordinary Share | GB00BP2C3V08 | ORD GBP0.0003 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.075 | -4.55% | 1.575 | 1.55 | 1.60 | 1.65 | 1.575 | 1.65 | 610,203 | 11:33:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 487k | -1.34M | -0.0046 | -3.41 | 4.59M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/11/2022 14:23 | Thanks for posting that moneymunch! | ![]() buzzzzzzzz | |
28/11/2022 13:58 | Longevity research is on the rise with Genflow latest to file for patent Leila Hawkins | 06/10/2022 Genflow is the latest biotech company to announce that it is working on therapeutics targeting aging and age-related diseases. The UK-based company is filing an international patent application in the US for variants of Sirtuin-6 (SIRT6), a gene variant found in centenarians that has been shown to promote longevity in mice. SIRT6 has been labelled the “longevity sirtuin” as it has the capacity to repair DNA damage that contributes to aging. Researchers are studying its preventative potential for cardiovascular diseases in particular, as a lack of SIRT6 causes inflammation and cell damage that can lead to atherosclerosis and heart failure among other conditions. The patent has been filed jointly with the University of Rochester, a prestigious private research university in New York. Genflow holds the exclusive license through the company’s Belgian subsidiary, Genflow Biosciences SRL. The rise of geroscience Scientific research into longevity has ramped up in recent years, with the rise in demand for products and technologies that enable people to take control of their health and live for longer. Earlier this year biotech startup Altos Labs was formed, with a mission to develop cell therapies that can halt or reverse the aging process. The US$3 bn company is backed by Amazon founder Jeff Bezos and has been called “t In a further sign that longevity research - also known as geroscience - is set to become the next breakthrough area of scientific research, the kingdom of Saudi Arabia has formed Hevolution Foundation, a non-profit organization set to invest $1 bn a year in the study of aging and therapies that can extend people’s lives. Commenting on the patent filing, Dr Eric Leire, Founder and CEO of Genflow, said: “I am proud of the excellent progress that Genflow has made by filing the patent and we look forward to contributing to the growing body of research on longevity, while also enhancing our patent portfolio. This marks a significant step in strengthening our IP position.” | ![]() moneymunch | |
28/11/2022 12:30 | Genflow Biosciences PLC (LSE:GENF) said it is confident about its future following three recent strategic collaborations in longevity research allied to a strong cash position. In March, Genflow commenced a scientific research collaboration with the University of Rochester's Aging Research Center (RoAR), one of the world's pre-eminent age research facilities. Data obtained from the collaboration will support the pre-clinical trials Genflow is undertaking and will expedite its development of gene therapies. In May, the company entered into a collaborative research agreement with Organips, a France-based biotechnology company, while in June it partnered with Magnitude Biosciences, a UK-based, specialist biotechnology research organisation that supports drug discovery and product development. Working with Magnitude will significantly expedite Genflow's future therapeutic developments, the company said. | ![]() moneymunch | |
28/11/2022 12:13 | Looking very nice. Gl :-) | ![]() moneymunch | |
28/11/2022 10:38 | Great spot, moneymunch. Huge upside from here. Looks like the rerate is getting under way. | ![]() felchandbart | |
28/11/2022 08:36 | Here's why this UK BioTech stock could be set to rally over 2000% | ![]() moneymunch | |
28/11/2022 08:36 | Here's why this UK BioTech stock could be set to rally over 2000% | ![]() moneymunch | |
15/11/2022 11:06 | Nice to see a bit of life in this. Not sure why that is. Very relaxed, company funded for next three years. | ![]() buzzzzzzzz | |
15/11/2022 09:37 | Be careful | ![]() ridingthewaves1 | |
26/10/2022 13:17 | What a disaster of a investment this has been to date | ![]() deadly nightshade | |
02/8/2022 10:03 | 2 mm's have gone to the bid so 3 v 1 atm, probably trying to give it a nudge and generate some buying | ![]() dave4545 | |
01/8/2022 13:53 | 2.75-2.755p spread So now you can buy size at the bid price and a full penny lower than recent director buys. | ![]() dave4545 | |
29/7/2022 13:51 | I like the look of this company. Have been invested here for a couple of weeks now, price has dropped slightly since then but clearly plenty of upside potential. Credible team and well-funded. Can't see it hanging around at these levels for too long. | ![]() felchandbart | |
28/7/2022 14:54 | Evil overhang in this NT to sell and 2.92p to buy, ignore the 3.5p offer mm are showing you can buy miles below that directors paid 3.7p recently but nobody cares | ![]() dave4545 | |
26/7/2022 15:23 | 3.34p paid for 127k But I can buy at 3.15p so somebody overpaid there or should have split trade | ![]() dave4545 | |
26/7/2022 14:16 | Think there has been a overhang all along. Even when it was flying it was hard to get a sell quote and easy to buy. Director buys in this market seem to mean nothing especially if small ones, 3-3.5p but you can buy miles inside at 3.17p | ![]() dave4545 | |
26/7/2022 11:57 | In this market MM's are frightened to hold any stock! | ![]() buzzzzzzzz | |
26/7/2022 08:24 | Below 3p - Don't think there are too many sellers below that - | ![]() tomboyb | |
26/7/2022 08:21 | And of course NT now to buy on the shake at 3p offer | ![]() dave4545 | |
26/7/2022 08:15 | Jeez watching all the mm's smash this up on some tiny selling. | ![]() dave4545 | |
26/7/2022 08:14 | Directors buy at 3.7p ok small lots but pi's sell out at 3p now ??? | ![]() dave4545 | |
22/7/2022 11:03 | Loads of buys just now but so weak they have all gone in the sell column but it does not take much to flip the book in this one If directors were paying 3.7p earlier in week they may well be topping up at 3.33p as well | ![]() dave4545 | |
22/7/2022 08:05 | I see that 31k was adjusted to 3.25p More massive trades, can they really be a rollover ? | ![]() dave4545 | |
21/7/2022 12:15 | I doubt you will see a worse sale this year than the 31k at 2.7p today 3 bid on L2 all quoting 30000 at 3.25p so why would you sell 1000 over NMS for a whopping 0.55p discount, they lost £150 for no reason at all except stupidity | ![]() dave4545 | |
20/7/2022 12:27 | What the vote down stalker. Yes I have one full time and one part time :-)) Does anybody care :-)) If all these little trades continue they might actually add up to a meaningful amount in the end. mm offering 3.74p atm | ![]() dave4545 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |